Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 4/20 | 0.50 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.44 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.44 |
| ▸ | CPT2 | P23786 | 2/20 | 0.43 |
| ▸ | CPT1A | P50416 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | JAK2 | O60674 | 1/20 | 0.42 |
| ▸ | JAK1 | P23458 | 1/20 | 0.42 |
| ▸ | PARP1 | P09874 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | ATR | Q13535 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3436730 | 0.81 | TRPV1 (0.52) | TRPV1HSD11B1TSHRGAAMEN1 | |
| SCHEMBL3436582 | 0.78 | POLB (0.52) | TRPV1TSHRMEN1MAPTKMT2A | |
| SCHEMBL3436723 | 0.77 | HTT (0.52) | TRPV1TSHRMEN1MAPTKMT2A | |
| SCHEMBL14423729 | 0.76 | TRPV1 (0.61) | TRPV1AVPR1AHSD11B1PARP1GAA | |
| SCHEMBL20339483 | 0.76 | TRPV1 (0.61) | TRPV1AVPR1AHSD11B1PARP1GAA | |
| SCHEMBL3086917 | 0.76 | CNR2 (0.52) | TRPV1TSHRMEN1MAPTKMT2A | |
| SCHEMBL14818767 | 0.75 | TRPV1 (0.56) | TRPV1AVPR1AHSD11B1PARP1 | |
| SCHEMBL3436727 | 0.74 | KMT2A (0.52) | TRPV1MEN1KMT2A | |
| SCHEMBL3436725 | 0.73 | ELANE (0.53) | TRPV1TSHRMAPTKMT2A | |
| SCHEMBL3436729 | 0.72 | CHRM4 (0.55) | TRPV1TSHRMEN1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163746-B2 | Azolecarboxamide derivative | ASTELLAS PHARMA INC. (JP) | 2012-04-24 | — | — | US | disclosed |
| US-8163746-B2 | Azolecarboxamide derivative | ASTELLAS PHARMA INC. (JP) | 2012-04-24 | — | — | US | disclosed |
| US-20090286766-A1 | AZOLECARBOXAMIDE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2009-11-19 | — | — | US | disclosed |
| US-20090286766-A1 | AZOLECARBOXAMIDE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2009-11-19 | — | — | US | disclosed |
| EP-2009005-A1 | AZOLECARBOXAMIDE DERIVATIVE | Astellas Pharma Inc. (JP) | 2008-12-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286766-A1 | AZOLECARBOXAMIDE DERIVATIVE | GPR17, NTRK1, TRPV1 | TRPV1 3/4885AVPR1A 1324/4885HSD11B1 3972/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.